New York, Feb 23, 2026, 08:22 EST — Premarket
- Spyre Therapeutics slid 4.2% in premarket trading, giving up ground after surging Friday.
- A new $500 million “shelf” registration just landed for investors, potentially funding trials but also set to dilute current holders.
- Initial Phase 2 data for ulcerative colitis is slated to arrive in the second quarter, with the company ready to kick things off.
Spyre Therapeutics dropped 4.2% to $41.38 in premarket action Monday, after its last trade came in at $43.21.
Shares pulled back after last week’s surge. Traders toggle between watching clinical milestones and wrestling with the usual biotech question: when the company might come back for another capital raise.
Spyre’s fresh filings put it in position to tap equity markets if conditions turn favorable, just as the company faces a stacked slate of trial readouts in 2026. For biotechs without commercial revenue, hitting the capital button like this can jolt the shares.
Shares jumped 14.3% Friday, reaching as high as $43.56 during the session, according to figures listed on the company’s investor relations quote page.
Spyre filed a Form S-3 shelf registration Thursday, seeking flexibility to raise as much as $500 million in securities when it chooses, not in a lump sum. The filing also spells out details of an at-the-market offering: Spyre has $154.1 million still available to sell from an earlier $200 million agreement, allowing it to issue shares at prevailing prices.
Spyre is pressing forward with its pipeline of long-acting antibody therapies for inflammatory bowel and rheumatic conditions, dropping fourth-quarter and full-year 2025 results after the bell Thursday. CEO Cameron Turtle called 2026 “a pivotal period,” saying Spyre plans to “unveil results” from several Phase 2 studies. The company closed out 2025 with about $757 million in cash, cash equivalents, and marketable securities—enough, it says, to keep operations running into the latter half of 2028. GlobeNewswire
According to a regulatory filing, the company released its financial results through a press release filed with the SEC.
Still, that kind of financing leeway comes with a downside. Having a shelf filed doesn’t necessarily mean a stock sale is imminent. After a big run-up, though, the overhang can weigh on shares—especially for clinical-stage firms spending heavily to keep trials moving.
The data is the obvious risk here. Spyre’s stock has rallied like a classic catalyst trade, but if enrollment faces delays, safety concerns arise, or initial efficacy underwhelms, those gains can vanish in a hurry.
Spyre is targeting the first readouts from Part A of its SKYLINE Phase 2 ulcerative colitis trial for Q2 2026, with investors already watching for those results.
